ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) INVESTOR ALERT: Investors With Large Losses in Rocket Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Rocket Pharmaceuticals, Inc. for alleged misrepresentations regarding the safety and clinical trial protocol of its drug RP-A501, which is intended for treating Danon disease [1][3]. Group 1: Lawsuit Details - The lawsuit covers investors who purchased Rocket's securities between February 27, 2025, and May 26, 2025 [1]. - Defendants are accused of failing to disclose serious risks associated with the clinical trial, including Serious Adverse Events (SAEs) and participant deaths [3]. - The company allegedly modified the trial protocol to include a new immunomodulatory agent without informing shareholders [3]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file by August 11, 2025 [4]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [4]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions [5].